GlassScriptPhysician profile
Maureen A Poplar
NPI 1124620893
$6,461.37
in general payments reported to CMS, 2019-2025
25 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,269 · 2022: $1,307 · 2023: $1,047 · 2024: $619 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,885.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $920.41 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $873.01 | 2021-2025 | Farxiga, Wainua |
| Abiomed | $652.59 | 2022-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.36 | 2021-2024 | Jardiance |
| Kestra Medical Technology Services, INC. | $467.78 | 2024-2025 | Assure Wcd |
| Medtronic, INC. | $445.55 | 2023-2025 | Micra, Aurora Ev-Icd Mri Surescan, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $431.56 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $326.27 | 2021-2024 | Xarelto |
| Amarin Pharma, INC. | $289.66 | 2021-2022 | |
| Cvrx, INC. | $233.28 | 2021-2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $200.40 | 2021-2023 | |
| Boston Scientific Corporation | $198.89 | 2022-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Merck Sharp & Dohme LLC | $186.22 | 2021-2024 | Verquvo |
| Biotronik INC. | $143.09 | 2022 | |
| Amgen INC. | $133.66 | 2021-2024 | Repatha |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $132.19 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.18 | 2022-2025 | |
| Esperion Therapeutics, INC. | $62.98 | 2021-2025 | Nexletol |
| Vifor Pharma, INC. | $41.11 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $39.13 | 2021-2025 | Eliquis |
| Kiniksa Pharmaceuticals, LTD. | $20.00 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $18.52 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bard Peripheral Vascular, INC. | $17.88 | 2022 | |
| Astellas Pharma US INC | $16.74 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Poplar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.